VivoSim Labs (NASDAQ:VIVS) Shares Up 2.6% – Should You Buy?

Shares of VivoSim Labs, Inc. (NASDAQ:VIVS) rose 2.6% during mid-day trading on Friday . The stock traded as high as $2.05 and last traded at $1.98. Approximately 14,438 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 41,178 shares. The stock had previously closed at $1.93.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, VivoSim Labs currently has an average rating of “Sell”.

VivoSim Labs Trading Up 2.6%

The company has a market cap of $5.17 million, a price-to-earnings ratio of -0.45 and a beta of 1.27. The stock’s 50-day moving average is $2.30 and its 200-day moving average is $2.28.

VivoSim Labs (NASDAQ:VIVS) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.98) earnings per share for the quarter. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%. The company had revenue of $0.03 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 8.23% of the company’s stock.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.